Charles Schwab’s BioXcel Therapeutics BTAI Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-203,615
| Closed | -$261K | – | 3513 |
|
|
2024
Q2 | $261K | Buy |
203,615
+12,645
| +7% | +$16.2K | ﹤0.01% | 3401 |
|
|
2024
Q1 | $539K | Buy |
190,970
+3,460
| +2% | +$9.76K | ﹤0.01% | 2996 |
|
|
2023
Q4 | $553K | Buy |
187,510
+50,707
| +37% | +$150K | ﹤0.01% | 3039 |
|
|
2023
Q3 | $346K | Sell |
136,803
-11,371
| -8% | -$28.8K | ﹤0.01% | 3186 |
|
|
2023
Q2 | $987K | Buy |
148,174
+4,281
| +3% | +$28.5K | ﹤0.01% | 2772 |
|
|
2023
Q1 | $2.69M | Buy |
143,893
+611
| +0.4% | +$11.4K | ﹤0.01% | 2443 |
|
|
2022
Q4 | $3.08M | Buy |
143,282
+2,789
| +2% | +$59.9K | ﹤0.01% | 2428 |
|
|
2022
Q3 | $1.66M | Buy |
140,493
+15,354
| +12% | +$182K | ﹤0.01% | 2630 |
|
|
2022
Q2 | $1.65M | Sell |
125,139
-10,171
| -8% | -$134K | ﹤0.01% | 2620 |
|
|
2022
Q1 | $2.83M | Buy |
135,310
+3,602
| +3% | +$75.3K | ﹤0.01% | 2530 |
|
|
2021
Q4 | $2.68M | Buy |
131,708
+1,744
| +1% | +$35.5K | ﹤0.01% | 2602 |
|
|
2021
Q3 | $3.95M | Buy |
129,964
+27,220
| +26% | +$826K | ﹤0.01% | 2475 |
|
|
2021
Q2 | $2.99M | Buy |
102,744
+6,723
| +7% | +$195K | ﹤0.01% | 2589 |
|
|
2021
Q1 | $4.15M | Buy |
96,021
+2,403
| +3% | +$104K | ﹤0.01% | 2381 |
|
|
2020
Q4 | $4.33M | Buy |
93,618
+2,743
| +3% | +$127K | ﹤0.01% | 2293 |
|
|
2020
Q3 | $3.94M | Buy |
90,875
+64,453
| +244% | +$2.8M | ﹤0.01% | 2192 |
|
|
2020
Q2 | $1.4M | Buy |
26,422
+11,190
| +73% | +$593K | ﹤0.01% | 2537 |
|
|
2020
Q1 | $341K | Buy |
15,232
+140
| +0.9% | +$3.13K | ﹤0.01% | 2837 |
|
|
2019
Q4 | $221K | Buy |
15,092
+2,556
| +20% | +$37.4K | ﹤0.01% | 3024 |
|
|
2019
Q3 | $89K | Hold |
12,536
| – | – | ﹤0.01% | 3097 |
|
|
2019
Q2 | $138K | Buy |
+12,536
| New | +$138K | ﹤0.01% | 3114 |
|